Penbrook Management LLC Reduces Stock Position in Mesoblast Limited (NASDAQ:MESO)

Penbrook Management LLC reduced its holdings in shares of Mesoblast Limited (NASDAQ:MESO) by 54.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 125,175 shares of the company’s stock after selling 150,175 shares during the quarter. Penbrook Management LLC’s holdings in Mesoblast were worth $627,000 as of its most recent SEC filing.

Mesoblast Stock Performance

NASDAQ MESO traded down $0.33 on Tuesday, reaching $6.45. The company’s stock had a trading volume of 240,067 shares, compared to its average volume of 1,215,783. Mesoblast Limited has a twelve month low of $1.61 and a twelve month high of $10.24. The firm’s 50 day moving average is $7.25 and its two-hundred day moving average is $4.33. The stock has a market cap of $736.46 million, a PE ratio of -5.71 and a beta of 3.48.

Analysts Set New Price Targets

Several brokerages recently weighed in on MESO. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a report on Thursday, June 20th. StockNews.com downgraded Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $13.67.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.